Immucell (ICCC) Cost of Revenue (2010 - 2026)

Immucell (ICCC) has reported Cost of Revenue for 17 consecutive years, with $4.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 30.93% year-over-year to $4.7 million; the trailing twelve-month figure through Jun 2026 stood at $16.2 million (down 8.21% YoY), and the FY2025 full-year result was $16.2 million, down 12.68% from the prior year.
• Cost of Revenue rose to $4.7 million in Q2 2026 per ICCC's latest filing, from $4.7 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $5.0 million in Q1 2024 and bottomed at $2.2 million in Q2 2022.
• Historically, Cost of Revenue has averaged $3.8 million across 5 years, with a median of $3.9 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue soared 70.46% in 2024, then fell 29.02% in 2025.
• Over 5 years, Cost of Revenue stood at $2.9 million in 2022, then jumped by 41.49% to $4.1 million in 2023, then gained by 19.13% to $4.9 million in 2024, then dropped by 4.14% to $4.7 million in 2025, then advanced by 0.7% to $4.7 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $4.7 million, $4.7 million, and $3.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.